BCMA/CD3 Bispecific Antibodies for Multiple Myeloma (MM) | Biopharma PEG
B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches | Leukemia
Updated Results of BCMA/CD19 Dual-targeting Fast CAR-T GC012F Dual-targeting CAR-T in RRMM | International Myeloma Foundation
BCMA-targeted immunotherapy for multiple myeloma | Journal of Hematology & Oncology | Full Text
A BCMA/CD16A bispecific innate cell engager for the treatment of multiple myeloma | Leukemia
Recombinant Human BCMA protein (ABIN4949075)
T-Cell Therapies mid-2020 Update - Blue Matter Consulting
Teclistamab Monotherapy for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma - touchONCOLOGY
Frontiers | Targeting BCMA to Treat Multiple Myeloma: Updates From the 2021 ASH Annual Meeting
L'antigène de maturation des cellules B (BCMA),une cible pour le myélome multiple - ACROBiosystems
Frontiers | Bispecific antibodies in multiple myeloma treatment: A journey in progress
IJMS | Free Full-Text | Characterization of BCMA Expression in Circulating Rare Single Cells of Patients with Plasma Cell Neoplasms
BCMA-targeted immunotherapy for multiple myeloma | Journal of Hematology & Oncology | Full Text
Frontiers | Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy
Therapeutic modalities in multiple myeloma. CD38, CD47, CD138, SLAMF7,... | Download Scientific Diagram
Recombinant Human BCMA protein (ABIN4949075)
IJMS | Free Full-Text | Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance
CD3/BCMA Bispecific Antibody for Multiple Myeloma Treatment - Protheragen
A BCMAxCD3 bispecific T cell–engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells - ScienceDirect
Target Expression, Generation, Preclinical Activity, and Pharmacokinetics of the BCMA-T Cell Bispecific Antibody EM801 for Multiple Myeloma Treatment - ScienceDirect
Hemato | Free Full-Text | Why Immunotherapy Fails in Multiple Myeloma
CAR T-cell therapy in multiple myeloma: more room for improvement | Blood Cancer Journal
CD3/BCMA Bispecific Antibody for Multiple Myeloma Treatment - Protheragen
Construction of BCMA-specific CAR and protocol of anti-BCMA CAR-T cell... | Download Scientific Diagram
Bispecific antibody targets in multiple myeloma (MM). BCMA, B-cell... | Download Scientific Diagram
